Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant746 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,430 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 1,560 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04881045 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | completed | Phase 1 | 29 | PfizerINDUSTRY | 2 | Jun 2, 2026 |
| NCT05918042 | A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation(OVARD) | completed | — | 414 | AstraZenecaINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT03430700 | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer(PROMPT) | completed | Phase 2 | 20 | University College, LondonOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04214210 | The DIALOGUE Study: Swiss-Korean Billateral Collaboration(DIALOGUE) | completed | N/A | 128 | University of BaselOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04295577 | Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR(MONITOR-UK) | completed | — | 388 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT00959647 | A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | completed | Phase 2 | 19 | Genentech, Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04726319 | Family History App in Personalized Medicine(FHAMe) | completed | N/A | 627 | University of TorontoOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07567573 | Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery(retroESGO ov1) | completed | — | 11,383 | European Society of Gynaecological OncologyOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04739527 | Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment(ALISON) | completed | Phase 1 | 17 | University Medical Center GroningenOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05613088 | A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 9 | Apr 30, 2026 | clinicaltrials |
| NCT02109367 | Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass | completed | — | 52 | Southern Illinois UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03732768 | Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis | completed | Phase 1 | 21 | Oncoinvent Solutions ASINDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT02854215 | Cost Utility of Radical Surgery in Ovarian Cancer(CURSOC) | completed | N/A | 200 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05021562 | A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice | completed | — | 354 | TakedaINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06973161 | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | completed | — | 140 | AstraZenecaINDUSTRY | 12 | Apr 8, 2026 | clinicaltrials |
| NCT04122235 | The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study(LETSGO) | completed | N/A | 755 | Sorlandet Hospital HFOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07241091 | SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive Surgery | completed | N/A | 60 | Adichunchanagiri Institute of Medical Sciences, B G NagaraOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06662435 | GYNecologic Cancer-Related COGnitive Impairment(GYNCOG) | completed | N/A | 60 | Northwestern UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04539327 | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | completed | — | 51 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT01247779 | Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy(ROBO-GYN) | completed | N/A | 386 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02867956 | Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06184867 | Choices About Genetic Testing And Learning Your Risk With Smart Technology(CATALYST) | completed | N/A | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04024254 | A Study of Serum Folate Levels in Patients Treated With Olaparib | completed | Phase 4 | 10 | Rush University Medical CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06624878 | Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer | completed | N/A | 568 | Zhejiang Cancer HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07439328 | ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer | completed | N/A | 30 | Institute of Oncology LjubljanaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03579394 | Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer(CHRONO) | completed | N/A | 211 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT02195973 | Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | completed | Phase 1 | 15 | University of Alabama at BirminghamOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01113112 | Biobehavioral-Cytokine Interactions in Ovarian Cancer(VEGF) | completed | — | 613 | Susan LutgendorfOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03763838 | Acupressure for Fatigue in Ovarian Cancer Survivors | completed | N/A | 171 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03707574 | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study | completed | — | 64 | National Cancer Institute (NCI)NIH | 2 | Feb 4, 2026 | clinicaltrials |
| NCT04457089 | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | completed | Early Phase 1 | 18 | Marc GoodmanOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06086665 | The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer(REFIRM) | completed | — | 850 | Asan Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus(RAF/MEK) | completed | Phase 1 | 104 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05646680 | A Performance Study of (Opportunistic) Salpingectomy(QOS) | completed | N/A | 115 | University Hospital, GhentOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04089189 | Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer(SABRINA) | completed | Phase 2 | 93 | Impact Therapeutics, Inc.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04640480 | Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors | completed | Phase 1 | 21 | SN BioScienceINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03622385 | Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer | completed | — | 10 | Baylor Research InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05360680 | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | completed | Phase 1 | 42 | Cue BiopharmaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05041257 | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers(PICCOLO) | completed | Phase 2 | 79 | AbbVieINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT06173037 | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | completed | Phase 2 | 43 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05483933 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | completed | Phase 1 | 86 | Shattuck Labs, Inc.INDUSTRY | 4 | Dec 23, 2025 | clinicaltrials |
| NCT06846099 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 | completed | Phase 1 | 69 | Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03027479 | Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss(METERMUS-IMC) | completed | N/A | 70 | University Hospital, ToursOTHER | 1 | Dec 22, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 2, 2026source: clinicaltrials